Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis

Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis

BackgroundPulmonary fibrosis is one of the sequelae of the COVID-19, which seriously affects the quality of life of survivors. Currently, there are no optimal evidence based guidelines targeting this population.Case PresentationWe report a 66-year-old female patient without underlying comorbidities...

Full description

Bibliographic Details
Main Authors: Xianglin Zhou, Danhui Yang, Xianglong Kong, Chengli Wei, Siqi LvQiu, Lin Wang, Yongkang Lin, Zhilan Yin, Zhiguo Zhou, Hong Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Medicine
Subjects:
pulmonary fibrosis
post-COVID-19
pirfenidone
long COVID
sequelae
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.925703/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.925703/full

Similar Items